help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 68, No. 4 740-743
doi:10.1210/jcem-68-4-740
Copyright © 1989 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FIORELLI, G.
Right arrow Articles by SERIO, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FIORELLI, G.
Right arrow Articles by SERIO, M.

Epidermal Growth Factor Receptors in Human Hyperplastic Prostate Tissue and Their Modulation by Chronic Treatment With a Gonadotropin-Releasing Hormone Analog*

GIANNA FIORELLI, ALESSANDRA DE BELLIS{dagger}, ANTONELLA LONGO, ALESSANDRO NATALI, ALFIERO COSTANTINI and MARIO SERIO

Endocrinology Unit, Departments of Clinical Physiopathology (G.F., A.D., A.L., M.S.) and Urology (A.N., A.C.), University of Florence Florence, Italy

Address all correspondence and requests for reprints to: Dr. Gianna Fiorelli, Endocrinology Unit, Department of Clinical Physiopathology, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.

We characterized the epidermal growth factor (EGF) receptor in the membrane fraction of prostatic tissue from men with benign prostatic hyperplasia (BPH). The maximum specific binding of [125I]EGF to the BPH membrane fraction was achieved after 30-min incubation at 35 C. Analysis of the binding data revealed two classes of binding sites, one of high affinity [Kd, 2.5 ± 0.5 (±SE) x 10–11 mol/L] and one of lower affinity (2.2 ± 0.3 x 10–9 mol/L). [125I]EGF binding was inhibited by excess EGF, but not by insulin, proinsulin, fibroblast growth factor, or insulin-like growth factors I and II. In prostatic tissue of men with BPH treated for 3 months with the GnRH agonist analog Goserelin (Zoladex, depot formulation), the binding capacities of both sites were significantly higher than those of BPH tissue from untreated men (P < 0.001). These results demonstrate that prostatic tissue from men with BPH contains two classes of specific binding sites for EGF, and their levels are modulated by chronic GnRH agonists treatment.

* This work was supported by a Grant from the Associazione Italiana per la Ricerca sul Cancro and a Grant from the University of Florence.

{dagger} Recipient of a fellowship from Sclavo (Siena, Italy).

Received July 25, 1988.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society